227 related articles for article (PubMed ID: 15479865)
1. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.
Calabrese LH; Zein N; Vassilopoulos D
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii18-ii24. PubMed ID: 15479865
[TBL] [Abstract][Full Text] [Related]
2. Treatment of rheumatic diseases in patients with HCV and HIV infection.
Galeazzi M; Giannitti C; Manganelli S; Benucci M; Scarpato S; Bazzani C; Caporali R; Sebastiani GD
Autoimmun Rev; 2008 Dec; 8(2):100-3. PubMed ID: 18694850
[TBL] [Abstract][Full Text] [Related]
3. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Carroll MB; Bond MI
Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
[TBL] [Abstract][Full Text] [Related]
4. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
[TBL] [Abstract][Full Text] [Related]
5. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.
Vassilopoulos D; Calabrese LH
Curr Opin Rheumatol; 2007 Nov; 19(6):619-25. PubMed ID: 17917544
[TBL] [Abstract][Full Text] [Related]
6. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.
Domm S; Cinatl J; Mrowietz U
Br J Dermatol; 2008 Dec; 159(6):1217-28. PubMed ID: 18945310
[TBL] [Abstract][Full Text] [Related]
7. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
[TBL] [Abstract][Full Text] [Related]
8. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
[No Abstract] [Full Text] [Related]
9. Mycobacterial disease in patients with rheumatic disease.
van Ingen J; Boeree MJ; Dekhuijzen PN; van Soolingen D
Nat Clin Pract Rheumatol; 2008 Dec; 4(12):649-56. PubMed ID: 19037226
[TBL] [Abstract][Full Text] [Related]
10. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
Winthrop KL
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
[TBL] [Abstract][Full Text] [Related]
11. Infectious complications of biologic agents.
Martin-Mola E; Balsa A
Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
[TBL] [Abstract][Full Text] [Related]
12. [Rheumatology. TNF alpha-inhibitors: infection risks? Practical recommendations].
Faucherre M; Pazar B; So A; Aubry-Rozier B
Rev Med Suisse; 2011 Jan; 7(277):75-6, 78-9. PubMed ID: 21309182
[TBL] [Abstract][Full Text] [Related]
13. Soft tissue infections.
Torralba KD; Quismorio FP
Rheum Dis Clin North Am; 2009 Feb; 35(1):45-62. PubMed ID: 19480996
[TBL] [Abstract][Full Text] [Related]
14. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
Strangfeld A; Listing J
Best Pract Res Clin Rheumatol; 2006 Dec; 20(6):1181-95. PubMed ID: 17127203
[TBL] [Abstract][Full Text] [Related]
15. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.
Cansu DU; Kalifoglu T; Korkmaz C
J Rheumatol; 2008 Mar; 35(3):421-4. PubMed ID: 18203328
[TBL] [Abstract][Full Text] [Related]
16. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection.
Linardaki G; Katsarou O; Ioannidou P; Karafoulidou A; Boki K
J Rheumatol; 2007 Jun; 34(6):1353-5. PubMed ID: 17552060
[TBL] [Abstract][Full Text] [Related]
17. Infection and anti-tumor necrosis factor-alpha therapy.
Zandman-Goddard G
Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
[No Abstract] [Full Text] [Related]
18. Hepatitis C-associated rheumatic disorders.
Buskila D
Rheum Dis Clin North Am; 2009 Feb; 35(1):111-23. PubMed ID: 19481000
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
20. Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection.
Galeazzi M; Bellisai F; Giannitti C; Manganelli S; Morozzi G; Sebastiani GD
Ann N Y Acad Sci; 2007 Sep; 1110():544-9. PubMed ID: 17911470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
